178 related articles for article (PubMed ID: 8847282)
21. Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension.
Choudhary G; Troncales F; Martin D; Harrington EO; Klinger JR
J Heart Lung Transplant; 2011 Jul; 30(7):827-33. PubMed ID: 21550822
[TBL] [Abstract][Full Text] [Related]
22. Effects of the endothelin ET(A) receptor antagonist, TA-0201, on pulmonary arteries isolated from hypoxic rats.
Itoh H; Yokochi A; Yamauchi-Kohno R; Maruyama K
Eur J Pharmacol; 1999 Jul; 376(3):233-8. PubMed ID: 10448881
[TBL] [Abstract][Full Text] [Related]
23. Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock.
Weitzberg E; Hemsén A; Rudehill A; Modin A; Wanecek M; Lundberg JM
Br J Pharmacol; 1996 Jun; 118(3):617-26. PubMed ID: 8762086
[TBL] [Abstract][Full Text] [Related]
24. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
[TBL] [Abstract][Full Text] [Related]
25. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit?
Clozel M
Ann Med; 2003; 35(8):605-13. PubMed ID: 14708970
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of CI-1020, an endothelin-A receptor antagonist, in hypoxic pulmonary hypertension.
Haleen S; Schroeder R; Walker D; Quenby-Brown E; Welch K; Hallak H; Uprichard A; Keiser J
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S331-5. PubMed ID: 9595473
[TBL] [Abstract][Full Text] [Related]
27. Exogenous nitric oxide centrally enhances pulmonary reactivity in the normal and hypertensive rat.
Schwenke DO; Pearson JT; Tsuchimochi H; Mori H; Shirai M
Clin Exp Pharmacol Physiol; 2005 Nov; 32(11):952-9. PubMed ID: 16405452
[TBL] [Abstract][Full Text] [Related]
28. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
Holm P
Scand Cardiovasc J Suppl; 1997; 46():1-40. PubMed ID: 9265559
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin II prevents hypoxic pulmonary hypertension and vascular changes in rat.
Rabinovitch M; Mullen M; Rosenberg HC; Maruyama K; O'Brodovich H; Olley PM
Am J Physiol; 1988 Mar; 254(3 Pt 2):H500-8. PubMed ID: 3348429
[TBL] [Abstract][Full Text] [Related]
30. Pulmonary vascular pressure effects by endothelin-1 in normoxia and chronic hypoxia: a longitudinal study.
Tjen-A-Looi S; Ekman R; Osborn J; Keith I
Am J Physiol; 1996 Dec; 271(6 Pt 2):H2246-53. PubMed ID: 8997280
[TBL] [Abstract][Full Text] [Related]
31. CPU0507, an endothelin receptor antagonist, improves rat hypoxic pulmonary artery hypertension and constriction in vivo and in vitro.
Yuan SH; Dai DZ; Guan L; Dai Y; Ji M
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1066-72. PubMed ID: 17042916
[TBL] [Abstract][Full Text] [Related]
32. Endothelin and pulmonary hypertension.
Chen YF; Oparil S
J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S49-53. PubMed ID: 10976782
[TBL] [Abstract][Full Text] [Related]
33. [Effects of thromboxane A2 on chronic hypoxic pulmonary hypertension in the rat].
Saito M; Tatsumi K; Kasahara Y; Sugito K; Igari H; Tani T; Kuriyama T
Nihon Kyobu Shikkan Gakkai Zasshi; 1996 Jan; 34(1):37-44. PubMed ID: 8717289
[TBL] [Abstract][Full Text] [Related]
34. BQ123, an ETA-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats.
Bonvallet ST; Zamora MR; Hasunuma K; Sato K; Hanasato N; Anderson D; Sato K; Stelzner TJ
Am J Physiol; 1994 Apr; 266(4 Pt 2):H1327-31. PubMed ID: 8184910
[TBL] [Abstract][Full Text] [Related]
35. Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat.
McCulloch KM; Docherty C; MacLean MR
Br J Pharmacol; 1998 Apr; 123(8):1621-30. PubMed ID: 9605569
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic hypercapnia prevents chronic hypoxia-induced pulmonary hypertension in the newborn rat.
Kantores C; McNamara PJ; Teixeira L; Engelberts D; Murthy P; Kavanagh BP; Jankov RP
Am J Physiol Lung Cell Mol Physiol; 2006 Nov; 291(5):L912-22. PubMed ID: 16829630
[TBL] [Abstract][Full Text] [Related]
37. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.
Hamidi SA; Lin RZ; Szema AM; Lyubsky S; Jiang YP; Said SI
Respir Res; 2011 Oct; 12(1):141. PubMed ID: 22029879
[TBL] [Abstract][Full Text] [Related]
38. Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat.
Underwood DC; Bochnowicz S; Osborn RR; Luttmann MA; Louden CS; Hart TK; Elliott JD; Hay DW
Pulm Pharmacol Ther; 1999; 12(1):13-26. PubMed ID: 10208832
[TBL] [Abstract][Full Text] [Related]
39. Prolonged nitric oxide inhalation fails to regress hypoxic vascular remodeling in rat lung.
Jiang BH; Maruyama J; Yokochi A; Iwasaki M; Amano H; Mitani Y; Maruyama K
Chest; 2004 Jun; 125(6):2247-52. PubMed ID: 15189948
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological characterization of 3-azabicyclo[3,2,1] octane-1-yl-l-leucyl-d-tryptophanyl-d-4-Cl-phenylalanine: A novel ET(A) receptor-selective antagonist.
Li X; Liu KL; Zheng JQ; Chi MG; Dong JJ; Dong SJ; Gong ZH
Pulm Pharmacol Ther; 2008 Oct; 21(5):780-7. PubMed ID: 18602014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
